HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

KR-31761

structure in first source
Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Yoo, Sung-Eun: 1 article (02/2009)
2. Lee, Chang-Soo: 1 article (02/2009)
3. Yang, Min-Kyu: 1 article (02/2009)
4. Lee, Byung-Ho: 1 article (02/2009)
5. Seo, Ho-Won: 1 article (02/2009)
6. Shin, Hwa-Sup: 1 article (02/2009)
7. Yi, Kyu-Yang: 1 article (02/2009)
8. Lee, Sung-Hun: 1 article (02/2009)
9. Chung, Hun-Jong: 1 article (02/2009)
10. Won, Hyung-Sik: 1 article (02/2009)

Related Diseases

1. Ischemia
02/01/2009 - "In isolated rat hearts subjected to 30-min global ischemia/30-min reperfusion, KR-31761 perfused prior to ischemia significantly increased both the left ventricular developed pressure (% of predrug LVDP: 17.8, 45.1, 54.2, and 62.6 for the control, 1 microM, 3 microM, and 10 microM, respectively) and double product (DP: heart rate x LVDP; % of predrug DP: 17.5, 44.9, 56.2, and 64.5 for the control, 1 microM, 3 microM, and 10 microM, respectively) at 30-min reperfusion while decreasing the left ventricular end-diastolic pressure (LVEDP). "
02/01/2009 - "The cardioprotective effects of KR-31761, a newly synthesized K+(ATP) opener, were evaluated in rat models of ischemia/reperfusion (I/R) heart injury. "
02/01/2009 - "KR-31761, a novel K+(ATP)-channel opener, exerts cardioprotective effects by opening both mitochondrial K+(ATP) and Sarcolemmal K+(ATP) channels in rat models of ischemia/reperfusion-induced heart injury."
02/01/2009 - "In anesthetized rats subjected to 30-min occlusion of left anterior descending coronary artery/2.5-h reperfusion, KR-31761 administered 15 min before the onset of ischemia significantly decreased the infarct size (72.2%, 55.1%, and 47.1% for the control, 0.3 mg/kg, i.v., and 1.0 mg/kg, i.v., respectively); and these effects were completely and almost completely abolished by 5-HD (10 mg/kg, i.v.) and HMR-1098, a selective blocker of sarcolemmal K+(ATP) (sarcK+(ATP)) channel (6 mg/kg, i.v.) administered 5 min prior to KR-31761 (72.3% and 67.9%, respectively). "
2. Heart Injuries
3. Contracture

Related Drugs and Biologics

1. L-Lactate Dehydrogenase (Lactate Dehydrogenase)
2. Adenosine Triphosphate (ATP)
3. HMR 1098